


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. West Valley Medical Center, Inc.</p> <p>2. 1717 Arlington Avenue Caldwell, ID 83605</p>	<p>In accordance with application dated August 29, 2022; and letter dated September 22, 2022,</p>	<p>4. Expiration Date: September 30, 2037</p>	
	<p>3. License No.: 11-27087-01 is renewed in its entirety to read as follows:</p>	<p>5. Docket No.: 030-32242 Reference No.:</p>	
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 500 millicuries total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.</p>



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 11-27087-01

Docket or Reference No.:
030-32242

Amendment No. 32

CONDITIONS

10. Licensed material shall be used or stored at the licensee's facilities located at 1717 Arlington Avenue, Caldwell, Idaho, 83605.
11. The Radiation Safety Officer (RSO) for this license is Teri Steele, B.S., CNMT, RT(N).
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User (M.D., D.O., etc.)</u> | <u>Material and Use</u> |
|---|--|
| Lyndon Carlos Box, M.D. | 35.100; 35.200 |
| Ashley Burt, M.D. | 35.100; 35.200; oral administration of sodium iodide I-131 |
| Janet M. Cegnar, M.D. | 35.100; 35.200 |
| Jared A. Chugg, M.D. | 35.100; 35.200; 35.300 |
| Michael A. Codina, M.D. | 35.100; 35.200 |
| Carolyn Ely Coffman, M.D. | 35.100; 35.200 |
| Curtis Coulam, M.D. | 35.100; 35.200; 35.300 |
| Ian Davey, M.D. | 35.100; 35.200; 35.300 |
| Neil Couchman Davey, M.D. | 35.100; 35.200 |
| Vicken Garabedian, M.D. | 35.100; 35.200 |
| Anthony P. Giauque, M.D. | 35.100; 35.200; 35.300 |
| Cyle Goodman, M.D. | 35.100; 35.200; oral administration of sodium iodide I-131 |
| Jason Hamblin, M.D. | 35.100; 35.200; oral administration of sodium iodide I-131 |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 11-27087-01

Docket or Reference No.:
030-32242

Amendment No. 32

Authorized User (M.D., D.O., etc.)Material and Use

Benjamin K. Hom, M.D.	35.100; 35.200; 35.300
John A. Jackson, M.D.	35.100; 35.200; 35.300
Christopher R. Kauffman, M.D.	35.100; 35.200; oral administration of sodium iodide I-131
Shane J. McGonegle, M.D.	35.100; 35.200; oral administration of sodium iodide I-131
Michael J. Modica, M.D.	35.100; 35.200; 35.300
Matt T. Moore, M.D.	35.100; 35.200; oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries
Gabriel Palmer, M.D.	35.100; 35.200; oral administration of sodium iodide I-131
Mark R. Papenfuss, M.D.	35.100; 35.200; 35.300
Saeed Payvar, M.D.	35.100; 35.200
Dallas D. Peck, M.D.	35.100; 35.200
Jason Patrick Salber, M.D.	35.100; 35.200; 35.300
Lisa M. Scales, M.D.	35.100; 35.200; 35.300
Howard B. Schaff, M.D.	35.100; 35.200; 35.300
Jeffrey Seabourn, M.D.	35.100; 35.200; 35.300
Bertram Jason Stemmler, M.D.	35.100; 35.200; oral administration of sodium iodide I-131
William L. Taylor, M.D.	35.100; 35.200; oral administration of sodium iodide I-131
Daniel John Wegner, M.D.	35.100; 35.200; 35.300

13. Sealed sources and source rods containing licensed material shall not be opened or sources removed from source holders or detached from source rods by the licensee, except as specifically authorized.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 11-27087-01

Docket or Reference No.:
030-32242

Amendment No. 32

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

A. Application dated August 29, 2022 (ML22242A114) and letter dated September 22, 2022 with enclosures (ML22266A261)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: September 26, 2022By: _____
Roberto J. Torres
Region IV